New Liver Perfusion Technique Cuts Transplant Complications by Nearly Half

Liver transplantation is a life-saving procedure, but donor organ quality remains a critical limiting factor. Extended-criteria donor livers — those from older or higher-risk donors — carry elevated risks of early failure after transplant. A new preservation strategy may change that equation significantly.

The Bridge to HOPE trial, published in JAMA Surgery, enrolled 219 patients across 15 U.S. liver transplant centers. Participants received extended-criteria donor livers and were randomized to either standard static cold storage (SCS) alone or SCS followed by back-to-base hypothermic oxygenated perfusion (HOPE). In the HOPE method, the liver is transported to the recipient hospital on ice, then actively chilled and oxygenated before being implanted.

The results were striking. Early allograft dysfunction — a measure of how well the liver functions in the first week post-transplant — occurred in just 20.2% of HOPE patients compared to 37.3% in the control group. Mean early allograft function scores were also significantly better in the HOPE group. Hospital stays were shorter too: 8 days versus 10.7 days on average. These improvements were significant enough that the trial was stopped early at interim analysis.

One-year graft and patient survival rates were similar between groups (95.4% vs 92.7% and 97.2% vs 96.4%, respectively), suggesting HOPE's primary benefit lies in reducing early complications rather than dramatically altering long-term survival — at least within the first year.

Commentators noted that other perfusion methods, including normothermic machine perfusion, are also widely used in the U.S., and head-to-head comparisons are still needed. The trial was open-label, and the patient population was predominantly male and white, which may limit generalizability. Still, HOPE's logistical simplicity and clear short-term benefits position it as a meaningful advance in transplant medicine.